Patents by Inventor Alfred R. Rudolph

Alfred R. Rudolph has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment or prevention of hemorrhagic viral infections with immunomodulator compounds
    Patent number: 8193152
    Abstract: An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: June 5, 2012
    Assignees: The Board of Regents of the University of Texas System, SciClone Pharmaceuticals, Inc.
    Inventors: Eric C. Mossel, Cynthia W. Tuthill, Alfred R. Rudolph, Clarence J. Peters
  • Treatment of melanoma
    Patent number: 8163702
    Abstract: An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: April 24, 2012
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Cynthia W. Tuthill, Alfred R. Rudolph
  • Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
    Patent number: 8029799
    Abstract: It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 4, 2011
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Paolo Carminati, Maria Gabriella Singrossi, legal representative, Roberto Camerini, Alfred R. Rudolph, Eduardo R. Martins
  • Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
    Patent number: 8017129
    Abstract: It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: September 13, 2011
    Assignee: SciClone Pharmaceuticals International Ltd
    Inventors: Paolo Carminati, Maria Gabriella Singross, legal representative, Roberto Camerini, Alfred R. Rudolph, Eduardo Martins
  • Methods of protecting against radiation damage using alpha thymosin
    Patent number: 7897567
    Abstract: Damage to cells and/or a subject caused by radiation is treated or prevented by administration of an alpha thymosin peptide.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: March 1, 2011
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Alfred R. Rudolph, Cynthia W. Tuthill
  • TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH ALPHA THYMOSIN PEPTIDES
    Publication number: 20100311656
    Abstract: An alpha thymosin peptide is administered to a patient having, or at risk of a respiratory viral infection, coronavirus infection and/or SARS.
    Type: Application
    Filed: June 16, 2010
    Publication date: December 9, 2010
    Applicant: SciClone Pharmaceuticals, Inc.
    Inventors: Alfred R. RUDOLPH, Cynthia W. TUTHILL
  • Alpha Thymosin Peptides as Cancer Vaccine Adjuvants
    Publication number: 20100092499
    Abstract: A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together.
    Type: Application
    Filed: December 6, 2005
    Publication date: April 15, 2010
    Applicant: SCICLONE PHARMACEUTICALS, INC.
    Inventors: Gustavo Antonio Moviglia, Alfred R. Rudolph
  • Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds
    Publication number: 20090143313
    Abstract: An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection.
    Type: Application
    Filed: October 27, 2005
    Publication date: June 4, 2009
    Applicant: SciClone Pharmaceuticals, Inc.
    Inventors: Eric C. Mossel, Cynthia W. Tuthill, Alfred R. Rudolph, Clarence J. Peters
  • TREATMENT OF MELANOMA
    Publication number: 20090088392
    Abstract: An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject.
    Type: Application
    Filed: April 13, 2007
    Publication date: April 2, 2009
    Applicant: SCICLONE PHARMACEUTICALS, INC.
    Inventors: Cynthia W. Tuthill, Alfred R. Rudolph
  • Immunomodulator Compounds as Vaccine Enhancers
    Publication number: 20090074815
    Abstract: A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine.
    Type: Application
    Filed: April 21, 2006
    Publication date: March 19, 2009
    Applicant: SCICLONE PHARMACEUTICALS, INC.
    Inventors: Cynthia W. Tuthill, Alfred R. Rudolph
  • Thymosin Alpha 1 Peptide/Polymer Conjugates
    Publication number: 20080152668
    Abstract: A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
    Type: Application
    Filed: October 2, 2007
    Publication date: June 26, 2008
    Applicant: SCICLONE PHARMACEUTICALS, INC.
    Inventors: Alfred R. RUDOLPH, Cynthia W. TUTHILL
  • Thymosin alpha 1 peptide/polymer conjugates
    Patent number: 7297676
    Abstract: A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: November 20, 2007
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Alfred R. Rudolph, Cynthia W. Tuthill
  • Treatment of hepatitis C with thymosin and peptide combination therapy
    Patent number: 7208167
    Abstract: A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: April 24, 2007
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventor: Alfred R. Rudolph
  • Thymosin alpha 1 peptide/.polymer conjugates
    Publication number: 20040248792
    Abstract: A pharmaceutical composition includes a physiologically active conjugate including a Thymosin alpha 1 (TA1) peptide conjugated to a material which increases half-life of the TA1 peptide in serum of a patient when the conjugate is administered to a patient. The material may be a substantially non-antigenic polymer. In a method of the invention, the substantially non-antigenic polymer is conjugated to a TA1 peptide. Compositions according to the invention are administered to patients in need of immune stimulation.
    Type: Application
    Filed: July 9, 2004
    Publication date: December 9, 2004
    Inventors: Alfred R. Rudolph, Cynthia W Tuthill
  • Treatment of hepatitis C with thymosin and peptide combination therapy
    Publication number: 20030185799
    Abstract: A method and pharmaceutical combination for treating hepatitis C by administering to a hepatitis C patient an effective amount of at least one alpha thymosin peptide, in combination with administration to the hepatitis C patient of an effective amount of at least one interferon, and optionally in combination with administration of at least one antiviral agent such as ribavirin.
    Type: Application
    Filed: February 7, 2003
    Publication date: October 2, 2003
    Inventor: Alfred R. Rudolph
  • Method of reducing side effects of chemotherapy in cancer patients
    Patent number: 6462017
    Abstract: A method for reducing the severity of chemotherapy side effects in cancer patients by administering thymosin &agr;1 in conjunction with the administration of a chemotherapy agent to the patient. As a result of the reduction of post-chemotherapy side effects, patients experience an increase in the quality of life.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: October 8, 2002
    Assignee: SciClone Pharmaceuticals, Inc.
    Inventors: Alfred R. Rudolph, Vincent Chung-Ying Tam, Maggie Jie Quan